Primary Jejunal Gastrointestinal Stromal Tumor: Diagnosis Delay of 3 Years but Successful Management in Early Stage (II) by Surgery and Adjuvant Therapy.
Ferdous Ara Begum, Md Arifur Rahman, Hashim Rabbi...
https://pubmed.ncbi.nlm.nih.gov/31602375Actively Recruiting
Led by Peking University People's Hospital · Updated on 2023-05-31
40
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating the use of minimal residual disease (MRD) detection through liquid biopsy to monitor postoperative recurrence and guide treatment in patients with high-risk gastrointestinal stromal tumors (GIST). The study focuses on patients who have undergone surgery and long-term treatment with the drug imatinib, aiming to evaluate whether a "drug holiday" approach, where medication is paused based on MRD results, affects progression-free survival, overall survival, and the development of drug resistance. This observational trial also examines the response to restarting imatinib if the disease progresses after drug withdrawal. This one-arm observational clinical trial follows a single group of high-risk GIST patients who have completed at least three years of imatinib after surgery with disease control and negative baseline MRD. Participants will stop taking imatinib and be monitored using MRD detection and imaging to observe recurrence or progression. If disease progression occurs, imatinib may be restarted. The study period includes up to three years of follow-up after entering the drug holiday phase to assess survival outcomes, drug re-use rates, genetic mutation changes, and comparison of MRD with imaging results. Participants will undergo regular clinical and imaging evaluations, along with blood tests to detect circulating tumor DNA, which helps track MRD status. Researchers will measure progression-free survival from the start of drug withdrawal until disease progression, as well as overall survival up to three years. The study requires patients to cooperate with follow-up visits, provide clinical and imaging data, and allow use of their test results for ongoing research. This careful monitoring aims to understand the potential benefits and risks of pausing imatinib based on MRD findings in high-risk GIST patients.
CONDITIONS
Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 years
Participants who have stopped imatinib treatment enter a monitoring phase using MRD detection and imaging to track disease recurrence and drug resistance.
Regular imaging and blood tests for MRD detection as scheduled by the study team
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
Z
Zhidong Gao, MD
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Ferdous Ara Begum, Md Arifur Rahman, Hashim Rabbi...
https://pubmed.ncbi.nlm.nih.gov/31602375M T Mazur, H B Clark
https://pubmed.ncbi.nlm.nih.gov/6625048Heikki Joensuu
https://pubmed.ncbi.nlm.nih.gov/18774375Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall...
https://pubmed.ncbi.nlm.nih.gov/32469385Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall...
https://pubmed.ncbi.nlm.nih.gov/22453568Chandrajit P Raut, N Joseph Espat, Robert G Maki...
https://pubmed.ncbi.nlm.nih.gov/30383140Yoon-Koo Kang, Hyung-Don Kim, Hyun Jin Kim...
https://pubmed.ncbi.nlm.nih.gov/36884149Robert H Howland
https://pubmed.ncbi.nlm.nih.gov/19772246Florent Mouliere, Alain R Thierry
https://pubmed.ncbi.nlm.nih.gov/22594497Chetan Bettegowda, Mark Sausen, Rebecca J Leary...
https://pubmed.ncbi.nlm.nih.gov/24553385